Cited by 324Coenzyme Q10 studies and effectsLipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study

Ghirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccioli, L., Caputo, S., Greco, A. V., Littarru, G. P.·1993·The Journal of Clinical Pharmacology

DOI 10.1002/j.1552-4604.1993.tb03948.x

Open this paper in CoChat — free account

Abstract

Inhibitors of HMG‐CoA reductase are new safe and effective cholesterol‐lowering agents. Elevation of alanine‐amino transferase (ALT) and aspartate‐amino transferase (AST) has been described in a few cases and a myopathy with elevation of creatinine kinase (CK) has been reported rarely. The inhibition of HMG‐CoA reductase affects also the biosynthesis of ubiquinone (CoQ10). We studied two groups of five healthy volunteers treated with 20 mg/day of pravastatin (Squibb, Italy) or simvastatin (MSD) for a month. Then we treated 30 hypercholesterolemic patients in a double‐blind controlled study with pravastatin, simvastatin (20 mg/day), or placebo for 3 months. At the beginning, and 3 months thereafter we measured plasma total cholesterol, CoQ10, ALT, AST, CK, and other parameters (urea, creatinine, uric acid, total bilirubin, gamma GT, total protein). Significant changes in the healthy volunteer group were detected for total cholesterol and CoQ10 levels, which underwent about a 40% reduction after the treatment. The same extent of reduction, compared with placebo was measured in hypercholesterolemic patients treated with pravastatin or simvastatin. Our data show that the treatment with HMG‐CoA reductase inhibitors lowers both total cholesterol and CoQ10 plasma levels in normal volunteers and in hypercholesterolemic patients. CoQ10 is essential for the production of energy and also has antioxidative properties. A diminution of CoQ10 availability may be the cause of membrane alteration with consequent cellular damage.

Integrity signals

Registry

Crossref · 10.1002/j.1552-4604.1993.tb03948.x

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,458
ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.
Endo, A., KURODA, M., & Tsujita, Y. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.1346 · Cited by 954
Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations.
Frei, B. B., Kim, M. C., & Ames, B. N. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.12.4879 · Cited by 626
Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy.
Ogasahara, S., Engel, A. G., Frens, D. B., & Mack, D. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.7.2379 · Cited by 365
Rhabdomyolysis in Patients Receiving Lovastatin after Cardiac Transplantation
East, C., Alivizatos, P. A., Grundy, S. M., Jones, P. H., & Farmer, J. A. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801073180111 · Cited by 291
Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial Hypercholesterolemia
Mabuchi, H., Haba, T., Tatami, R., Miyamoto, S., Sakai, Y., Wakasugi, T., Watanabe, A., Koizumi, J., & Takeda, R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198108273050902 · Cited by 262
Myolysis and Acute Renal Failure in a Heart-Transplant Recipient Receiving Lovastatin
Norman, D. J., Illingworth, D. R., Munson, J. L., & Hosenpud, J. D. (1988) · New England Journal of Medicine · doi:10.1056/nejm198801073180110 · Cited by 255
Rhabdomyolysis and Renal Injury With Lovastatin Use
Corpier, C. L. (1988) · JAMA · doi:10.1001/jama.260.2.239 · Cited by 236
The participation of coenzyme Q in free radical production and antioxidation
Beyer, R. E. (1990) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(90)90154-b · Cited by 209

Show all 23 references

Research works printed but not linked: 9

Lipid Research Clinics Program, 1984, The lipid research clinics coronary primary prevention trial I. Reduction in incidence of coronary heart disease, JAMA, 25, 31
Stamler J, 1984, Is relationship between serum cholesterol and risk of premature death from coronary heart disease continous and graded, JAMA, 251, 365
Brown MS, 1980, Multivalent feedback regulation of HMG‐CoA reductase, a control mechanism coordinating isoprenoid syntesis and cell growth, J Lipid Res, 319, 24
Crane FL, 1984, Biomedical and Clinical Aspect of Coenzyme Q.
Kobayashi M, 1980, Structural effects of ubiquinones on the mitochondrial inner membrane, J Appl Biochem, 2, 270
Beyer RE, 1987, The function of Coenzyme Q in free radical production and as an antioxidant: a review, Chemica Scripta, 27, 145
Mortensen A, 1986, Biomedical Aspects of Coenzyme Q., 39
Frustaci A, 1986, Biomedical Aspects of Coenzyme Q., 157
Beyer RE, 1990, Highlights in Ubiquinone Research., 191

Sorted by citations

Statin-associated myopathy
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Lipidomics reveals a remarkable diversity of lipids in human plasma
Quehenberger, O., Armando, A. M., Brown, A. H., Milne, S. B., Myers, D. S., Merrill, A. H., Bandyopadhyay, S., Jones, K. N., Kelly, S., Shaner, R. L., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m009449 · Cited by 1,341
Metabolism and function of coenzyme Q
Turunen, M., Olsson, J., & Dallner, G. (2004) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2003.11.012 · Cited by 1,026
Antiatherothrombotic Properties of Statins
Rosenson, R. S., & Tangney, C. (1998) · JAMA · doi:10.1001/jama.279.20.1643 · Cited by 954
Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.
Huerta-Alardin, A. L., Varón, J., & Marik, P. E. (2004) · Critical Care · doi:10.1186/cc2978 · Cited by 910
Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities
Sivitz, W. I., & Yorek, M. A. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2531 · Cited by 742
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 583
The Role of Coenzyme Q10 in Statin-Associated Myopathy
Marcoff, L., & Thompson, P. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.049 · Cited by 537
The Effect of Coenzyme Q 10 on Morbidity and Mortality in Chronic Heart Failure
Mortensen, S. A., Rosenfeldt, F., Kumar, A., Dolliner, P., Filipiak, K. J., Pella, D., Alehagen, U., Steurer, G., & Littarru, G. P. (2014) · JACC: Heart Failure · doi:10.1016/j.jchf.2014.06.008 · Cited by 488
Self-citation
Narrative review: statin-related myopathy
Joy, T. R., & Hegele, R. A. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00009 · Cited by 453
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Effect of Coenzyme Q10 on myopathic symptoms in patients treated with statins
Caso, G., Kelly, P., McNurlan, M. A., & Lawson, W. E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.12.063 · Cited by 286
An Assessment of Statin Safety by Muscle Experts
Thompson, P. D., Clarkson, P. M., & Rosenson, R. S. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.013 · Cited by 263
Lipid‐lowering drugs and mitochondrial function: effects of HMG‐CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio
DE PINIEUX, G., CHARIOT, P., AMMI‐SAÏD, M., LOUARN, F., LEJONC, J. L., ASTIER, A., JACOTOT, B., & GHERARDI, R. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.04178.x · Cited by 262
Genetic risk factors associated with lipid-lowering drug-induced myopathies
Vladutiu, G. D., Simmons, Z., Isackson, P. J., Tarnopolsky, M., Peltier, W. L., Barboi, A. C., Sripathi, N., Wortmann, R. L., & Phillips, P. S. (2006) · Muscle & Nerve · doi:10.1002/mus.20567 · Cited by 253
Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome
Kumar, A., Kaur, H., Devi, P., & Mohan, V. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.07.003 · Cited by 237
Comparison of One-Year Efficacy and Safety of Atorvastatin Versus Lovastatin in Primary Hypercholesterolemia
Davidson, M. H., McKenney, J. M., Stein, E. A., Schrott, H. G., Bakker-Arkema, R. G., Fayyad, R. S., & Black, D. M. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00174-4 · Cited by 233
Atorvastatin Decreases the Coenzyme Q10 Level in the Blood of Patients at Risk for Cardiovascular Disease and Stroke
Rundek, T., Naini, A., Sacco, R. L., Coates, K., & DiMauro, S. (2004) · Archives of Neurology · doi:10.1001/archneur.61.6.889 · Cited by 229
Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors
Mortensen, S. A., Leth, A., Agner, E., & Rohde, M. (1997) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(97)00014-9 · Cited by 199
Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials
Banach, M., Serban, C., Ursoniu, S., Rysz, J., Muntner, P., Toth, P. P., Jones, S. R., Rizzo, M., Glasser, S. P., Watts, G. F., et al. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.07.008 · Cited by 195
Coenzyme Q10 and statins: Biochemical and clinical implications
Littarru, G. P., & Langsjoen, P. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.002 · Cited by 188
Self-citation
Squalene epoxidase as hypocholesterolemic drug target revisited
Chugh, A. (2002) · Progress in Lipid Research · doi:10.1016/s0163-7827(02)00029-2 · Cited by 188
Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference
Mancini, G. B. J., Baker, S. K., Bergeron, J., FITCHETT, D. H., Frohlich, J. J., Genest, J. J., Gupta, M., Hegele, R. A., Ng, D. S., & Pope, J. E. (2011) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2011.05.007 · Cited by 187
Nutraceutical therapies for atherosclerosis
Moss, J. W. E., & Ramji, D. P. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.103 · Cited by 193
Effect of coenzyme Q10 supplementation on simvastatin-induced myalgia
Young, J. M., Florkowski, C. M., Molyneux, S. L., McEwan, R. G., Frampton, C. M., George, P. M., & Scott, R. S. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.030 · Cited by 185
Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis
Fotino, A. D., Thompson‐Paul, A. M., & Bazzano, L. (2012) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.040741 · Cited by 185
Statins: pros and cons
Pinal‐Fernandez, I., Casal-Domínguez, M., & Mammen, A. L. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.11.030 · Cited by 192
Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans
Laaksonen, R., Jokelainen, K., Sahi, T., Tikkanen, M. J., & Himberg, J.-J. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90266-x · Cited by 177
Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem
Zozina, V. I., Covanţev, S., Goroshko, O. A., Красных, Л. М., & Kukes, V. G. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x14666180416115428 · Cited by 177
Preparation of a carboxymethylcellulose-iron composite for uptake of atorvastatin in water
Ali, I., Alharbi, O. M. L., ALOthman, Z. A., Al‐Warthan, A., & Al-Mohaimeed, A. M. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.03.211 · Cited by 176
The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle
Laaksonen, R., Jokelainen, K., Laakso, J., Sahi, T., Härkönen, M., Tikkanen, M. J., & Himberg, J.-J. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89180-1 · Cited by 171
Effects of coenzyme Q10 supplementation (300 mg/day) on antioxidation and anti-inflammation in coronary artery disease patients during statins therapy: a randomized, placebo-controlled trial
Lee, B., Tseng, Y., Yen, C., & Lin, P. (2013) · Nutrition Journal · doi:10.1186/1475-2891-12-142 · Cited by 174
Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia
Draeger, A., Monastyrskaya, K., Mohaupt, M., Hoppeler, H., Savolainen, H., Allemann, C., & Babiychuk, E. (2006) · The Journal of Pathology · doi:10.1002/path.2018 · Cited by 163
Clinical implications of pharmacogenomics of statin treatment
Mangravite, L. M., Thorn, C. F., & Krauss, R. M. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500384 · Cited by 164
The Other Medical Causes of Rhabdomyolysis
Allison, R. C., & Bedsole, D. L. (2003) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200308000-00005 · Cited by 159
Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin
Morand, O. H., Aebi, J. D., Dehmlow, H., Ji, Y., Gains, N., Lengsfeld, H., & Himber, J. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37449-6 · Cited by 159
Toxic and drug-induced myopathies
Dalakas, M. C. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.168294 · Cited by 157
Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle
Sirvent, P., Mercier, J., Vassort, G., & Lacampagne, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.070 · Cited by 154
Overview of the use of CoQ10 in cardiovascular disease
Langsjoen, P. H., & Langsjoen, A. M. (1999) · BioFactors · doi:10.1002/biof.5520090224 · Cited by 147
Mechanisms of statin-associated skeletal muscle-associated symptoms
Bouitbir, J., Sanvee, G. M., Panajatovic, M. V., Singh, F., & Krähenbühl, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.010 · Cited by 152
Micronutrient Deficiencies
Soukoulis, V., Dihu, J. B., Sole, M. J., Anker, S. D., Cleland, J. G. F., Fonarow, G. C., Metra, M., Pasini, E., Strzelczyk, T. A., Taegtmeyer, H., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.08.012 · Cited by 140
Molecular clues into the pathogenesis of statin‐mediated muscle toxicity
Baker, S. K. (2005) · Muscle & Nerve · doi:10.1002/mus.20291 · Cited by 137
Therapeutic use of coenzyme Q 10 and coenzyme Q 10 -related compounds and formulations
Villalba, J. M., Parrado‐Fernández, C., González, M. S., & Alcain, F. J. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003727495 · Cited by 139
Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue
Rosenfeldt, F., Marasco, S., Lyon, W. J., Wowk, M., Sheeran, F. L., Bailey, M., Esmore, D. S., Davis, B. B., Pick, A., Rabinov, M., et al. (2004) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2004.03.034 · Cited by 131
Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats
Schaefer, W. H., Lawrence, J. W., Loughlin, A. F., Stoffregen, D. A., Mixson, L. A., Dean, D. C., Raab, C. E., Yu, N. X., Lankas, G. R., & Frederick, C. B. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.08.013 · Cited by 131
Muscular Side Effects of Statins
Sinzinger, H. F., Wolfram, R. M., & Peskar, B. A. (2002) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200208000-00001 · Cited by 127
Lactic Acidosis: Recognition, Kinetics, and Associated Prognosis
Vernon, C., & LeTourneau, J. L. (2010) · Critical Care Clinics · doi:10.1016/j.ccc.2009.12.007 · Cited by 125
Reduction of Serum Ubiquinol-10 and Ubiquinone-10 Levels by Atorvastatin in Hypercholesterolemic Patients
Mabuchi, H., Higashikata, T., Kawashiri, M., Katsuda, S., Mizuno, M., Nohara, A., Inazu, A., Koizumi, J., & Kobayashi, J. (2005) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12.111 · Cited by 119
Targeting the Metabolic Response to Statin-Mediated Oxidative Stress Produces a Synergistic Antitumor Response
McGregor, G. H., Campbell, A. D., Fey, S. K., Tumanov, S., Sumpton, D. P., Blanco, G. R., Mackay, G., Nixon, C., Vázquez, A., Sansom, O. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0644 · Cited by 116
Phenolic profiles, antihyperglycemic, antihyperlipidemic, and antioxidant properties of pomegranate (Punica granatum) peel extract
El‐Hadary, A. E., & Ramadan, M. F. (2019) · Journal of Food Biochemistry · doi:10.1111/jfbc.12803 · Cited by 130
The clinical use of HMG CoA‐reductase inhibitors and the associated depletion of coenzyme Q 10 . A review of animal and human publications
Langsjoen, P. H., & Langsjoen, A. M. (2003) · BioFactors · doi:10.1002/biof.5520180212 · Cited by 112
Evidence of Drug–Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update
Mohn, E. S., Kern, H., Saltzman, E. J., Mitmesser, S. H., & McKay, D. L. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10010036 · Cited by 121
Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors
Jamal, S. M., Eisenberg, M. J., & Christopoulos, S. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.12.037 · Cited by 111
COQ4 Mutations Cause a Broad Spectrum of Mitochondrial Disorders Associated with CoQ10 Deficiency
Brea‐Calvo, G., Haack, T. B., Karall, D., Ohtake, A., Invernizzi, F., Carrozzo, R., Kremer, L. S., Dusi, S., Fauth, C., Scholl‐Bürgi, S., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2014.12.023 · Cited by 110
Coenzyme Q10: Absorption, Antioxidative Properties, Determinants, and Plasma Levels
Kaikkonen, J., Tuomainen, T., Nyyssönen, K., & Salonen, J. T. (2002) · Free Radical Research · doi:10.1080/10715760290021234 · Cited by 107
Coenzyme q10 and statin-induced mitochondrial dysfunction.
Deichmann, R. E., Lavie, C. J., & Andrews, S. S. (2010) · PubMed Central · Cited by 107
Rhabdomyolysis Associated with Concomitant Use of Atorvastatin and Cyclosporine
Maltz, H. C., Balog, D. L., & Cheigh, J. S. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.19039 · Cited by 104
Coenzyme Q10 Supplementation and Heart Failure
Singh, U. S., Devaraj, S., & Jialal, I. (2007) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00306.x · Cited by 104
Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction
Silver, M. A., Langsjoen, P. H., Szabo, S., Patil, H., & Zelinger, A. B. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.07.121 · Cited by 102
Simvastatin
Plosker, G. L., & McTavish, D. (1995) · Drugs · doi:10.2165/00003495-199550020-00009 · Cited by 102
Rosuvastatin: Beyond the cholesterol-lowering effect
Cortese, F., Gesualdo, M., Cortese, A. M., Carbonara, S., Devito, F., Zito, A., Ricci, G., Scicchitano, P., & Ciccone, M. M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.012 · Cited by 98
Determinants of plasma coenzyme Q10 in humans
Kaikkonen, J., Nyyssönen, K., Tuomainen, T.-P., Ristonmaa, U., & Salonen, J. T. (1999) · FEBS Letters · doi:10.1016/s0014-5793(98)01712-8 · Cited by 97
Role of Coenzyme Q10 in Chronic Heart Failure, Angina, and Hypertension
Tran, M. T., Mitchell, T. M., Kennedy, D. T., & Giles, J. T. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.9.797.34564 · Cited by 96
The Effect of HMG-CoA Reductase Inhibitors on Coenzyme Q10: Possible Biochemical/Clinical Implications
Hargreaves, I. P., Duncan, A. J., Heales, S. J. R., & Land, J. M. (2005) · Drug Safety · doi:10.2165/00002018-200528080-00002 · Cited by 91
Statin myopathies: pathophysiologic and clinical perspectives.
Baker, S. K., & Tarnopolsky, M. A. (2001) · PubMed · Cited by 90
Effect of Coenzyme Q10 supplementation on statin-induced myalgias
Bookstaver, D. A., Burkhalter, N. A., & Hatzigeorgiou, C. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.04.026 · Cited by 89
Coenzyme Q10: is there a clinical role and a case for measurement?
Molyneux, S. L., Young, J. M., Florkowski, C. M., Lever, M., & George, P. M. (2008) · PubMed Central · Cited by 87
Pharmacogenomics of cholesterol-lowering therapy
Schmitz, G., & Langmann, T. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.07.012 · Cited by 86
Nonpharmacologic Treatment of Dyslipidemia
Houston, M. C., Fazio, S., Chilton, F. H., Wise, D. E., Jones, K. B., Barringer, T. A., & Bramlet, D. A. (2009) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.02.002 · Cited by 85
YM‐53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species
Ugawa, T., Kakuta, H., Moritani, H., Matsuda, K., Ishihara, T., Yamaguchi, M., Naganuma, S., Iizumi, Y., & Shikama, H. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703545 · Cited by 82
HMG-CoA reductase inhibitors and coenzyme Q10
Nawarskas, J. J. (2005) · Cardiology in Review · doi:10.1097/01.crd.0000154790.42283.a1 · Cited by 80
Understanding coenzyme Q
Wang, Y., Lilienfeldt, N., & Hekimi, S. (2024) · Physiological Reviews · doi:10.1152/physrev.00040.2023 · Cited by 88
Statins and myotoxicity: a therapeutic limitation
Tiwari, A. K., Bansal, V. S., Chugh, A., & Mookhtiar, K. A. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.5.651 · Cited by 80
Statins induce calcium-dependent mitochondrial permeability transition
Velho, J. A., Okanobo, H., Degasperi, G. R., Matsumoto, M. Y., Alberici, L. C., Cosso, R. G., Oliveira, H. C. F., & Vercesi, A. E. (2005) · Toxicology · doi:10.1016/j.tox.2005.11.007 · Cited by 77
Presymptomatic Neuromuscular Disorders Disclosed Following Statin Treatment
Tsivgoulis, G. K., Spengos, K. M., Karandreas, N., Πάνας, Μ., Kladi, A., & Manta, P. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.14.1519 · Cited by 77
The effect of pravastatin and atorvastatin on coenzyme Q10
Bleske, B. E., Willis, R. A., Anthony, M. J., Casselberry, N., Datwani, M., Uhley, V. E., Secontine, S. G., & Shea, M. J. (2001) · American Heart Journal · doi:10.1067/mhj.2001.116762 · Cited by 77
Coenzyme Q10and selenium in statin-associated myopathy treatment
Fedacko, J., Pella, D., Fedackova, P., Hänninen, O., Tuomainen, P., Jarcuska, P., Lopuchovsky, T., Jedlickova, L., Merkovska, L., & Littarru, G. P. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2012-0118 · Cited by 76
Self-citation
Chalcones as putative hepatoprotective agents: Preclinical evidence and molecular mechanisms
Karimi‐Sales, E., Mohaddes, G., & Alipour, M. R. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.022 · Cited by 76
Inhibitory effect of novel diallyldisulfide analogs on HMG-CoA reductase expression in hypercholesterolemic rats: CREB as a potential upstream target
Kumar, S., Sharma, M., & Tiwari, M. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.05.020 · Cited by 75
Molecular mechanisms of statin intolerance
Gluba-Brzózka, A., Franczyk, B., Toth, P. P., Rysz, J., & Banach, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.59938 · Cited by 73
Effects of ubiquinone (coenzyme Q10) on myopathy in statin users
Schaars, C. F., & Stalenhoef, A. F. H. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283168ecd · Cited by 74
Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction
Singh, R. B., Neki, N. S., Kartikey, K., Pella, D., Kumar, A., Niaz, M. A., & Thakur, A. S. (2003) · Springer eBooks · doi:10.1007/978-1-4615-0298-2_11 · Cited by 74
American Association of Clinical Endocrinologists Medical Guidelines for the Clinical Use of Dietary Supplements and Nutraceuticals
Mechanick, J. I., Brett, E. M., Chausmer, A. B., Dickey, R. A., Wallach, S., Bergman, D. A., Garber, J. R., Hamilton, C. R., Handelsman, Y., Holdy, K. E., et al. (2003) · Endocrine Practice · doi:10.4158/ep.9.5.417 · Cited by 73
Pharmacogenetics of Statin-Induced Myotoxicity
Kee, P. S., Chin, P. K. L., Kennedy, M. A., & Maggo, S. D. S. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.575678 · Cited by 73
Statin Treatment Increases Lifespan and Improves Cardiac Health in Drosophila by Decreasing Specific Protein Prenylation
Spindler, S. R., Li, R., Dhahbi, J. M., Yamakawa, A., Mote, P. L., Bodmer, R., Ocorr, K. A., Williams, R. T., Wang, Y., & Ablao, K. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039581 · Cited by 71
The Relationship between Coenzyme Q10, Oxidative Stress, and Antioxidant Enzymes Activities and Coronary Artery Disease
Lee, B., Lin, Y., Huang, Y., Ko, Y., Hsia, S., & Lin, P. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/792756 · Cited by 73
Dermatomyositis‐like syndrome and HMG‐CoA reductase inhibitor (statin) intake
Vasconcelos, O. M., & Campbell, W. W. (2004) · Muscle & Nerve · doi:10.1002/mus.20127 · Cited by 71
Current and future trends in the lipid lowering therapy
Okopień, B., Bułdak, Ł., & Bołdys, A. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.03.016 · Cited by 69
Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors
Bargossi, A., Grossi, G., Fiorella, P. L., Gaddi, A. V., Giulio, R. D., & Battino, M. A. (1994) · Molecular Aspects of Medicine · doi:10.1016/0098-2997(94)90028-0 · Cited by 69
Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
Bargossi, A., Battino, M. A., Gaddi, A. V., Fiorella, P. L., Grossi, G., Barozzi, G., Giulio, R. D., Descovich, G. C., Sassi, S., Genova, M. L., et al. (1994) · International Journal of Clinical & Laboratory Research · doi:10.1007/bf02592449 · Cited by 69
A role for reduced coenzyme Q in atherosclerosis?
Thomas, S. R., Witting, P. K., & Stocker, R. (1999) · BioFactors · doi:10.1002/biof.5520090216 · Cited by 68
EFFICACY OF SIMVASTATIN AND PUMPKIN-SEED OIL IN THE MANAGEMENT OF DIETARY-INDUCED HYPERCHOLESTEROLEMIA
AL-ZUHAIR, H., El-Fattah, A. A. A., & Latif, H. A. A. E. (1997) · Pharmacological Research · doi:10.1006/phrs.1997.0148 · Cited by 67
The management of conditioned nutritional requirements in heart failure
Allard, M. L., Jeejeebhoy, K. N., & Sole, M. J. (2006) · Heart Failure Reviews · doi:10.1007/s10741-006-9195-3 · Cited by 68
Use of Statins and the Risk of Parkinson???s Disease
Becker, C., Jick, S. S., & Meier, C. R. (2008) · Drug Safety · doi:10.2165/00002018-200831050-00004 · Cited by 66
Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction
Singh, R. B., Neki, N. S., Kartikey, K., Pella, D., Kumar, A., Niaz, M. A., & Thakur, A. S. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1023408031111 · Cited by 66
Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy
Schmitz, G., & Drobnik, W. (2003) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2003.088 · Cited by 64
In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin‐induced adverse effects
Guis, S., Figarella‐Branger, D., Mattei, J., Nicoli, F., Fur, Y. L., Kozak-Ribbens, G., Pellissier, J., Cozzone, P. J., Amabile, N., & Bendahan, D. (2006) · Arthritis Care & Research · doi:10.1002/art.22100 · Cited by 64
CoQ10Function and Role in Heart Failure and Ischemic Heart Disease
Ayer, A., Macdonald, P. S., & Stocker, R. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034258 · Cited by 65
Ubiquinone supplementation during lovastatin treatment: effect on LDL oxidation ex vivo
Palomäki, A., Malminiemi, K., Solakivi, T., & Malminiemi, O. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32524-4 · Cited by 61
Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor
von Keutz, E., & Schlüter, G. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00424-x · Cited by 59

Authors: Ghirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccioli, L., Caputo, S., Greco, A. V., & Littarru, G. P.
Affiliations: Università Cattolica del Sacro Cuore (IT)
Corresponding author: Ghirlanda, G.
ORCID: Uccioli, L.
Caputo, S.
Venue: The Journal of Clinical Pharmacology
Publisher: Wiley
Published: 1993-03
Volume: 33
Issue: 3
Pages: 226-229
ISSN: 0021-9754 (ISSN-L)
0091-2700
1552-4604
DOI: 10.1002/j.1552-4604.1993.tb03948.x
OpenAlex: W1964874366
Cited by: 324
References: 23
Citations by year: 2026: 2 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 5 · 2018: 15 · 2017: 12 · 2016: 17 · 2015: 16 · 2014: 11 · 2013: 8 · 2012: 16
FWCI: 1.55
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 7312 d)
Locations: The Journal of Clinical Pharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords: statins, coenzyme Q10, pravastatin, simvastatin, hypercholesterolemia, serum cholesterol, statin adverse effects, creatine kinase, liver enzymes, myopathy
MeSH terms: Adult, Cholesterol, Double-Blind Method, Female, Humans, Hypercholesterolemia, Lipids, Lovastatin, Male, Middle Aged, Ubiquinone, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks